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Abstract
Background: Critically ill patients in the intensive care unit (ICU) are at risk of clinically important gastrointestinal
bleeding, and acid suppressants are frequently used prophylactically. However, stress ulcer prophylaxis may increase
the risk of serious adverse events and, additionally, the quantity and quality of evidence supporting the use of
stress ulcer prophylaxis is low. The aim of the SUP-ICU trial is to assess the benefits and harms of stress ulcer
prophylaxis with a proton pump inhibitor in adult patients in the ICU. We hypothesise that stress ulcer prophylaxis
reduces the rate of gastrointestinal bleeding, but increases rates of nosocomial infections and myocardial ischaemia.
The overall effect on mortality is unpredictable.
Methods/design: The SUP-ICU trial is an investigator-initiated, pragmatic, international, multicentre, randomised,
blinded, parallel-group trial of stress ulcer prophylaxis with a proton pump inhibitor versus placebo (saline) in 3350
acutely ill ICU patients at risk of gastrointestinal bleeding. The primary outcome measure is 90-day mortality.
Secondary outcomes include the proportion of patients with clinically important gastrointestinal bleeding,
pneumonia, Clostridium difficile infection or myocardial ischaemia, days alive without life support in the 90-day
period, serious adverse reactions, 1-year mortality, and health economic analyses.
The sample size will enable us to detect a 20 % relative risk difference (5 % absolute risk difference) in 90-day
mortality assuming a 25 % event rate with a risk of type I error of 5 % and power of 90 %. The trial will be
externally monitored according to Good Clinical Practice standards. Interim analyses will be performed after 1650
and 2500 patients.
Conclusion: The SUP-ICU trial will provide high-quality data on the benefits and harms of stress ulcer prophylaxis
with a proton pump inhibitor in critically ill adult patients admitted in the ICU.
Trial registration: ClinicalTrials.gov Identifier: NCT02467621.
Keywords: Stress ulcer prophylaxis, Gastrointestinal bleeding, Intensive care unit, Critically ill, Randomised clinical
trial, Placebo, Adverse event
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Background
Critically ill patients are at risk of stress-related
gastrointestinal (GI) mucosal damage, ulceration and
bleeding [1]. Endoscopic studies have shown that gas-
tric erosions are present in up to 90 % of patients by
the third day in the intensive care unit (ICU) [2, 3].
These lesions are, in the vast majority of patients,
superficial and asymptomatic, but some can progress
and result in overt and clinically important GI bleed-
ing [4]. Clinically important GI bleeding in the ICU is
a serious condition, with an estimated one- to four-
fold increased risk of death and excess length of ICU
stay of 4–8 days [1, 5]. It has been suggested that
prophylaxis with acid suppressants reduces the risk of
GI bleeding and hence the risk of death [6]. In this
context, stress ulcer prophylaxis (SUP) was introduced
and is recommended in international guidelines [7–
10] and regarded as standard of care in the ICU [5,
11]. However, clinical research has not been able to
confirm that SUP improves outcome [12]. A recent
meta-analysis comprising 20 randomised clinical trials
(RCTs) comparing proton pump inhibitors (PPIs) and/
or histamine-2-receptor antagonists (H2RAs) versus
placebo or no prophylaxis did not find any differences
in patient important outcome measures between the
SUP and the placebo/no prophylaxis groups [12]. Fur-
thermore, concern has been expressed about poten-
tially increased risks of side effects in patients
receiving prophylactic treatment with acid suppres-
sants [13–16]. The higher gastric pH in these patients
may compromise host immunity and increase the risk
of pneumonia and Clostridium difficile infection
(CDI) [15, 17]. However, no meta-analyses of rando-
mised trials have shown a significantly increased risk
of nosocomial pneumonia when using SUP compared
to placebo/no prophylaxis [12, 18]. Additionally, no
trials have assessed the incidence of CDI in an ICU
setting, but a recently published large cohort study
found a 2–4 fold increased risk of CDI in adult
mechanically ventilated patients receiving PPIs com-
pared to H2RAs [19]. Studies conducted outside the
ICU have demonstrated similar findings [20, 21].
Also, an association between the use of PPIs and an
increased risk of cardiovascular events has been sug-
gested [18, 22, 23].
Taken together, the balance between benefits and
harms of SUP is unclear in critically ill patients in
the ICU. The aim of the SUP-ICU trial is to assess
the benefits versus harms of PPI (pantoprazole) in
acutely ill adults in the ICU. We hypothesise that a
PPI reduces the rates of GI bleeding, but increases
the rates of nosocomial infections and myocardial is-
chaemia. The effect on overall mortality is, therefore,
unpredictable.
Methods
Trial design
The SUP-ICU trial is an investigator-initiated, prag-
matic, international, multicentre, randomised, blinded,
parallel-group trial of SUP with a PPI versus placebo.
Approvals
The trial is approved by the Danish Health and Medicine
Agency (2015030166), the Committees on Health Re-
search Ethics in the Capital Region of Denmark (H-
15003141) and the Danish Data Protection Agency (RH-
2015-3203695) and registered at ClinicalTrials.gov (Iden-
tifier: NCT02467621).
Setting
European ICUs admitting adult patients.
Population
Inclusion criteria
All adult (18 years or older) patients who are acutely ad-
mitted to the ICU with one or more risk factors for GI
bleeding [5]:
 Shock (continuous infusion with vasopressors or
inotropes, systolic blood pressure below 90 mmHg,
mean arterial blood pressure below 70 mmHg or
plasma lactate level 4 mmol/l or above)
 Acute or chronic intermittent or continuous renal
replacement therapy (RRT)
 Invasive mechanical ventilation which is expected to
last more than 24 hours
 Coagulopathy (platelets below 50 × 109/l, or
international normalised ratio (INR) above 1.5, or
prothrombin time (PT) above 20 s) documented
within the last 24 hours
 Ongoing treatment with anticoagulant drugs
(prophylactic doses excluded)
 History of coagulopathy (platelets below 50 × 109/l
or INR above 1.5 or PT above 20 s within the
6 months prior to hospital admission)
 History of chronic liver disease (portal hypertension,
cirrhosis proven by biopsy, computed tomography
(CT) scan or ultrasound or history of variceal
bleeding or hepatic encephalopathy)
Exclusion criteria
 Contraindications to PPIs (including intolerance
of PPIs and treatment with atazanavir (anti-
human immunodeficiency virus (HIV)
medication))
 Current daily treatment with a PPI and/or a H2RA
 GI bleeding of any origin during current hospital
admission
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 Diagnosed with peptic ulcer during current hospital
admission
 Organ transplant during current hospital admission
 Withdrawal from active therapy or brain death
 Fertile woman with positive test for urinary or
plasma human chorionic gonadotropin (hCG)
 Consent according to national regulations not
obtainable
Trial medication
Enrolled patients will be randomised to receive either
pantoprazole 40 mg (pantoprazole, Actavis, Gentofte,
Denmark) or placebo, given once daily intravenously,
from randomisation until ICU discharge or death for a
maximum of 90 days. Identical vials with and without
pantoprazole powder will be masked with a full covering
label. The nurse caring for the patient will have access
to an electronic medication distribution system, which
allows the allocation of the appropriate vial to the pa-
tient. The nurse will add 10 ml of sodium chloride to
the vial, shake it, and administer the contents intraven-
ously to the patient. As the powder immediately dis-
solves to a colourless fluid it will not be possible to
distinguish dissolved pantoprazole in sodium chloride
from sodium chloride alone.
Outcome measures
Primary outcome measure
All-cause mortality 90 days after randomisation
Secondary outcome measures
 Proportion of patients with one or more of the
following adverse events during ICU stay: clinically
important GI bleeding, pneumonia, CDI, or acute
myocardial ischaemia
 Proportion of patients with clinically important GI
bleeding during ICU stay
 Proportion of patients with one or more infectious
adverse events (pneumonia or CDI) during ICU stay
 Days alive without use of mechanical ventilation,
RRT or circulatory support in the 90-day trial period
 Number of serious adverse reactions (SARs) during
ICU stay
 Mortality 1 year after randomisation
 A health economic analysis will be performed. The
analytic details will be based on the results of the
trial and specified at that time (cost-benefit versus
cost-minimisation analyses)
The specific elements of the composite outcomes will
be reported in the primary publication.
Definitions
See Appendix 1.
Screening
All patients referred to a participating clinical trial site
will be considered for participation (screened). Patients
will be eligible if they fulfil all of the inclusion criteria
and none of the exclusion criteria listed. Inclusion and
exclusion of patients (including reasons for exclusion)
will be reported according to the Consolidated Standards
of Reporting Trials (CONSORT) statement [24].
Randomisation
Staff at trial sites will have 24-hour access to web-based
central randomisation allowing immediate and concealed
allocation of trial medication. Randomisation will be per-
formed in blocks with varying block sizes according to
the generation of the allocation sequence by the
Copenhagen Trial Unit (CTU) [25]. A unique patient
identification number will be entered into the system to
ensure that the patient is not randomised twice. In
addition, each patient will be allocated a unique patient
number (screening number).
Blinding
The allocated trial medication will be blinded to the pa-
tient, the clinical staff caring for the patient, the investi-
gators, the outcome assessors, the data manager, the
statistician conducting the analyses, and the writing
committee when drafting the abstract for the primary
publication.
An independent company (Nomeco Clinical Trial Sup-
ply Management (CTSM) [26]) will handle masking,
coding and distribution of the vials containing the inves-
tigational medicinal product (IMP)/placebo. A computer
programme will generate the coding list (CTU) with
numbers for the vials. Each trial site will have a sufficient
number of vials to be allocated to participating patients.
This will ensure that the patient only receives the trial
intervention they are randomised to receive.
Safety
Patients can be withdrawn from the trial if:
 A clinical indication for treatment with a PPI/H2RA
arises (GI bleeding and/or ulcer/gastritis/varices
verified endoscopically). Patients will receive
treatment for GI bleeding according to local standards
 Another clinical indication for withdrawal than the
above mentioned (judged by responsible clinician or
local investigator)
 A SAR/suspected unexpected serious adverse
reaction (SUSAR) occurs (see below)
 The patient or next of kin withdraws consent
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The independent Data Monitoring and Safety Com-
mittee (DMSC) can recommend pausing or stopping the
trial. Details are provided in Appendix 2.
Serious adverse reactions
Adverse reactions are specified in the product character-
istics of pantoprazole. The following conditions related
to the intervention will be considered SARs:
 Anaphylactic reactions
 Agranulocytosis
 Pancytopenia
 Acute hepatic failure
 Stevens-Johnson syndrome and toxic epidermal
necrolysis
 Interstitial nephritis
 Angioedema (Quincke’s oedema)
The occurrence of SARs will be recorded daily in the
electronic case report form (eCRF) during ICU stay and
the distribution of SARs in the two groups will be com-
pared by the DMSC at the interim analyses. During the
trial the sponsor will send a yearly report to the ethics
committees and medicine agencies.
SUSARs are defined as serious adverse events (SAEs)
not described in the product characteristics for panto-
prazole. SUSARs will be reported by the trial site investi-
gators to the sponsor within 24 hours. The sponsor will
report any SUSAR to the medicine agency within 7 days.
SAEs will not be recorded as an entity because the ma-
jority of ICU patients will experience a number of SAEs
during their critical illness. SAEs will be captured in the
secondary outcome measures.
Patient withdrawal
Patients who are withdrawn from the trial intervention
will be followed-up and included in the intention-to-
treat analysis. Patients may be withdrawn from the trial
according to national consent regulations. In order to
limit the amount of missing data, as much data as pos-
sible from each patient will be collected. All randomised
patients will be reported, and all data available with con-
sent will be used [27].
Patients who are transferred to another ICU will be
regarded as discharged from the ICU unless the new
ICU is an active SUP-ICU trial site. If so, the allocated
trial intervention will be continued. All patients trans-
ferred to another ICU will be followed-up for the pri-
mary outcome measure.
Statistics
A predefined analysis plan will be prepared and pub-
lished before data analysis.
The primary analysis will include the intention-to-
treat population comparing mortality 90 days after ran-
domisation in the two groups by binary logistic regres-
sion analysis with adjustment for stratification variables:
site and active haematological cancer. A secondary ana-
lysis will be performed adjusting for stratification vari-
ables together with other known major prognostic co-
variates: age, baseline Sequential Organ Failure Assess-
ment (SOFA) score, and type of admission (medical,
elective surgery or emergency surgery). A sensitivity ana-
lysis will be conducted including the per-protocol popu-
lation, excluding patients with a major protocol violation
(patients who did not receive the allocated trial interven-
tion at all, patients who did not receive the trial inter-
vention for at least 2 days in a row, treatment with a PPI
or a H2RA without clinical indication and withdrawal
from trial intervention). The prevalence and pattern of
missing values will be collected and analysed according
to the predefined statistical analysis plan. If missingness
exceeds 5 % and data is not missing completely at ran-
dom (Little’s test <0.05) multiple imputation with at least
10 imputations will be performed, and the primary result
of the analysis will be from the aggregated intervention
effects from the imputed datasets. All statistical tests will
be two-tailed and P < 0.05 will be considered statistically
significant.
Sample size estimation
Assuming a baseline 90-day mortality of 25 % [5] (see
Appendix 3), α = 0.05 (two-sided), and β = 0.1, 3350 pa-
tients (2 × 1675) will be needed to show a 20 % relative
risk reduction (RRR) or increase (RRI) corresponding to
a 5 % absolute risk reduction or risk increase in the pri-
mary outcome measure.
Interim analyses
Interim analyses will be performed after 1650 and
2500 patients. The DMSC may recommend pausing
or stopping the trial if the group difference in the
primary outcome measure, SARs or SUSARs is found
at the interim analyses with statistical significance
levels adjusted according to the LanDeMets group se-
quential monitoring boundaries based on the O’Brien-
Fleming alpha-spending function, or otherwise finds
that the continued conduct of the trial clearly com-
promises patient safety.
Data registration
Data will be entered into a web-based eCRF (CTU)
by trial or clinical personnel. From the eCRF the trial
database will be established. Paper case report forms
(CRFs) will be used in case of technical difficulties
with the eCRF. Details on data collection are shown
in Appendix 1.
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Data handling and retention
Data will be handled according to the national data pro-
tection agencies. All original records (including consent
forms, CRFs, SUSAR reports and relevant correspon-
dences) will be retained at trial sites or the CTU for
15 years to allow inspection by the Good Clinical Prac-
tice (GCP) Unit or local authorities. The trial database
will be maintained for 15 years and anonymised if re-
quested by the authorities.
Monitoring
The trial will be externally monitored according to a
monitoring plan developed in collaboration with the
GCP Unit in Copenhagen, which will coordinate the
monitoring done by local GCP Units and/or monitors in
all countries. Trial site investigators will give access to
source data. A centralised day-to-day monitoring of the
eCRF will be done by the coordinating investigator or
her delegates.
Ethical justification
The trial will adhere to the latest version of the Helsinki
Declaration [28] and the national laws in the participat-
ing countries. Inclusion will start after approval by the
ethical committees, medicines agencies and data protec-
tion agencies.
Stress ulceration is a condition often seen in critically
ill patients in the ICU [1]. The majority of patients will
be temporarily incompetent because of severe illness or
as a consequence of the treatment, including sedation.
We cannot perform the trial in competent patients be-
cause less sick (and thus competent) patients do not suf-
fer from stress ulcers. Patients requiring acute treatment
in the ICU, e.g. mechanical ventilation, are in an acute
life-threatening condition and it would expose the pa-
tient to great risk not to initiate the necessary treatment
in order to obtain informed consent. To conduct clinical
trials with the goal of improving the outcome for ICU
patients at risk of stress-related GI bleeding, it is neces-
sary to randomise and enrol patients before obtaining
their informed consent. Informed consent will be ob-
tained from all participants or representatives according
to the national regulations. The process leading to the
achievement of consent may differ in the participating
countries, but will be described and be in compliance
with all applicable local regulations.
No biological material will be collected for the trial;
thus, no bio-bank will be formed.
Enrolment
Patients from Denmark, Finland, Italy, The Netherlands,
Norway, Switzerland and the United Kingdom are ex-
pected to participate in the trial. The trial will be initi-
ated in Denmark in January 2016 followed by the other
countries when national approvals are obtained. The
trial is expected to recruit patients during a 2-year
period.
Trial management and organisation
The trial is part of the SUP-ICU research programme
[29] and is supported by the Centre for Research in In-
tensive Care (CRIC) and the CTU.
A Steering Committee has been formed consisting of
all national principal investigators and a Management
Committee (see Appendix 4). The Steering Committee
will manage and coordinate the trial centrally.
A local research team consisting of a principal investi-
gator and a trial coordinator will manage and coordinate
the trial locally. The principal investigator has the re-
sponsibility for data collection and maintenance of trial
documentation.
Co-enrolment of participants in other interventional
trials has to be approved by the SUP-ICU Steering Com-
mittee, but is generally allowed.
Publication
Upon trial completion the main manuscript with trial re-
sults, whether positive, negative or neutral, will be sub-
mitted for peer-review to one of the major clinical
journals. Furthermore, the results will be published at
the SUP-ICU web page [29].
The Steering Committee will grant authorship depend-
ing on personal input according to the Vancouver Princi-
ples. The DMSC and investigators not qualifying for
authorship will be acknowledged with their names under
the ‘SUP-ICU trial investigators’ in an appendix to the
final manuscript.
Data sharing
According to the recommendations from the Institute of
Medicine and the Scandinavian Trial Alliance a clean file
dataset used for final analysis of the main results of the
trial, the statistical analysis plan, a variable explanation,
and the protocol will be made publicly accessible in an
anonymised form 2 years after the last follow-up of the
last patients [30].
Timeline
2014–2015: applications for funding, ethical committees
and medicine agencies, development of an eCRF, devel-
opment of monitoring plan and education of clinical
staff
2016–2017: inclusion of patients
2018: data analyses, writing and submission of the
main manuscript for publication
2021: data sharing according to the CRIC contract be-
tween partners [31]
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Collaborators
The trial has been developed and conducted in collabor-
ation with the Scandinavian Critical Care Trial Group
(SCCTG). The trial is administered by the CRIC [31].
The CTU has developed the eCRF in close collaboration
with the Steering Committee. The web-based random-
isation system and the system for allocation of trial
medication have been developed and administered by
the CTU. Pharma-Skan ApS produces the placebo vials
and Nomeco CTSM masks and distributes trial medica-
tion to all sites.
Finances
The trial is funded by the Innovation Fund Denmark
and supported by the Aase and Ejnar Danielsens Foun-
dation, the Ehrenreichs Foundation, the Scandinavian
Society of Anaesthesia and Intensive Care Medicine
(SSAI), the Danish Society of Anaesthesiology and Inten-
sive Care Medicine (DASAIM), the Danish Medical As-
sociation, and the European Society of Intensive Care
Medicine. Patient insurances will be sought financed
from public and private funds. The funding sources will
have no influence on trial design, trial conduct, data
handling, data analysis or publication.
Discussion
Trial rationale
Clinical trials have suggested that there is a reduction in
the incidence of GI bleeding among ICU patients receiv-
ing SUP compared with ICU patients receiving placebo
or no prophylaxis [3, 32–38]. Based on this research
conducted 15–20 years ago, and because of potentially
increased mortality and morbidity in patients with clin-
ically important bleeding, SUP is recommended as a
standard of care in critically ill patients [7]. Around 75 %
of critically ill patients in the ICU receive an acid sup-
pressant during their ICU stay and PPIs are the most
frequently used agents [5]. However, the quantity and
quality of evidence supporting a reduction in clinically
important GI bleeding and mortality with these agents is
low [12]. Importantly, it has been suggested that PPIs
may increase the risk of pneumonia, CDI, and acute
myocardial ischaemia, and SUP may, in the worst case
scenarios, increase mortality [13–16]. Taken together,
SUP with a PPI is standard of care in ICUs worldwide
but has never been tested in large high-quality clinically
placebo-controlled trials. As a consequence, PPIs have
been used as SUP for several years without convincing
evidence of improved outcome.
Population
The population in this trial constitutes adult patients
acutely admitted to the ICU with one or more risk fac-
tors for GI bleeding [5].
Intervention
In recent years a PPI has been considered the drug of
choice in the management of most acid-related GI
disorders [39]. The superior efficacy of PPIs over
H2RAs has been demonstrated in various GI disor-
ders, including peptic ulcer disease [39], and rando-
mised trials and meta-analyses have assessed PPIs
compared to H2RAs as SUP in the ICU. A recently
published meta-analysis by Alhazzani et al. (14 trials,
1720 patients) compared a PPI and a H2RA [40], and
found that a PPI was more efficient in reducing clin-
ical important and overt GI bleeding, but no differ-
ences were shown regarding mortality, length of stay
or incidence of pneumonia [40].
In most countries PPIs are more frequently used as
SUP than H2RAs [5]. Since PPIs are considered equally
effective, and pantoprazole is the most frequently used
PPI [5], we chose this as the intervention.
Comparator
As described in the previous section, it has been sug-
gested that a PPI is superior to a H2RA in the preven-
tion of clinically important and overt GI bleeding.
However, before comparing different SUP agents we
need firm evidence of SUP being superior to placebo.
This information is currently not available [12].
Outcome
Assessing mortality as the primary outcome has a num-
ber of advantages. First, mortality has not been the pri-
mary outcome of previous trials and we are sceptical
that previous trials have collected high-quality data on
mortality other than short-term mortality (ICU/hospital)
[12]. Second, nearly all previous trials assessing PPIs or
H2RAs as SUP have high risks of bias [12]. We know
that trials with high risks of bias tend to overestimate
benefit and underestimate harm [41]. Accordingly, previ-
ous trial results might be biased and even though they
seem to find a neutral effect on mortality this may be a
biased estimate actually concealing excess mortality in
the SUP group. Third, meta-analysis of previous trials
did not reach a realistic information size so even neutral
mortality estimates may be misleading [12]. Fourth, as a
consequence of the 6S trial [42], where we found that
bleeding was associated with death and that death was
partly mediated by bleeding (and renal insufficiency), it
appears less likely that there should be a clinically sig-
nificant reduction in GI bleeding (if PPIs do prevent GI
bleeding) without any effect on mortality [43]. Conse-
quently, assessing mortality as the primary outcome
measure gives the opportunity to weigh up potential
benefits and harms.
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Sample size
It is difficult to produce reliable sample size estimations
according to anticipated effects on GI bleeding because
we have no reliable control group data due to the wide-
spread use of PPIs [5]. As a consequence, it has been ne-
cessary to calculate sample size estimations given that
something may change if we stop/avoid using PPIs until
GI bleeding actually happens (see Appendix 3). The
chosen intervention effect of 20 % RRR or RRI of the
primary outcome may seem high, but in a population
with septic shock or in, e.g. patients after cardiac arrest,
a 20 % hazard ratio reduction corresponds to 1 month
of extra median survival in patients with a median sur-
vival time of approximately 5 months. Furthermore,
3350 patients included in a low-risk-of-bias trial would
make a huge contribution to existing evidence, more
than doubling the number of randomised patients and
providing trial results with low risk of bias on mortality
and SAEs. Additionally, trial sequential analysis (TSA)
[44, 45] of existing trials (n = 16) has shown that 34 %
(1584 patients) of the required information size to detect
or reject a 20 % RRR has been accrued; corresponding to
a required information size of 4575 patients [12] (see
Appendix 5). Consequently, there is an information gap
of around 3000 patients assuming a 20 % RRR in mortal-
ity. With the inclusion of an additional 3350 patients it
is expected that the pooled effect will cross the boundary
for benefit/harm or the boundary for futility.
However, no single trial, whether large or well-
conducted, gives the final answer and the SUP-ICU trial
will not be an exception. Thus, existing meta-analyses of
SUP should be updated with the SUP-IUC trial results.
Strengths
The SUP-ICU trial is a large multicentre clinical trial de-
signed to provide high-quality data with low risk of bias.
The trial is monitored according to GCP standards, and
before data analyses a statistical analysis plan will be
available. Furthermore, the strengths include concealed
group assignment, blinding of the patient, the clinical
staff caring for the patient, the investigators, the out-
come assessors, the data manager, and the trial statisti-
cian. The trial design is pragmatic with routine practice
maintained except from prescription of SUP; with result-
ing high generalisability.
Prior to designing the trial we have thoroughly described
the available evidence in systematic reviews and a meta-
analysis with TSA [12, 46]. Determining the incidence of GI
bleeding in critically ill patients in the ICU is complicated
by varying definitions of the outcome, difficulties in meas-
uring the outcome, and differences in case mix. To make
sure the available data on GI bleeding and risk factors were
valid and up-to-date we conducted a large international ob-
servational study assessing the incidence of GI bleeding,
risk factors for GI bleeding, and the use of SUP in more
than 1000 adult critically ill patients in the ICU [5].
Limitations
As already described in previous sections the sample size es-
timation is based on estimates, as we do not have valid data
describing mortality among patients with risk factors for GI
bleeding not treated with a PPI due to the widespread use of
acid suppressants. The power for even major effects on each
of the possible side effects (pneumonia, CDI and acute myo-
cardial ischaemia) may be reduced, but it will still make a
large contribution to our knowledge on these outcomes that
may seriously question, overthrow or confirm what we know
so far. Furthermore, assessing the potential side effects as a
composite outcome measure will increase the power. Add-
itionally, there is a risk of excluding high-risk patients as pa-
tients already receiving daily treatment with a PPI or a
H2RA cannot be enrolled in the trial due to the risk of dis-
continuing a therapy for another indication, e.g. history of
peptic ulcer. The definition of overt GI bleeding includes
haematochezia which might occur from a lower GI bleeding
source not affected by PPI, e.g. colonic bleeding. Finally, we
do not assess the use of a H2RA or other SUP agents and
will not be able to draw conclusions about these drugs.
Perspective
The SUP-ICU trial will provide important high-quality
data and the results will inform clinicians, guideline
committee members and policy-makers on the use of
SUP in ICU patients. Together with existing data the
trial will establish a more solid evidence base for the use
of a prophylactic PPI in critically ill patients in the ICU.
Trial status
Recruiting. First patient planned for inclusion in January 2016.
Appendix 1. Definitions used in the SUP-ICU trial
Definition of stratification variables
Site: all participating intensive care units (ICUs) will be
assigned a number identifying the department.
Haematological malignancy includes any of the following:
Leukemia: acute lymphoblastic leukemia (ALL), acute
myelogenous leukemia (AML), chronic myelogenous
leukemia (CML), chronic lymphocytic leukemia (CLL).
Lymphoma: Hodgkin’s disease, non-Hodgkin lymph-
oma (e.g. small lymphocytic lymphoma (SLL), diffuse
large B-cell lymphoma (DLBCL), follicular lymphoma
(FL), mantle cell lymphoma (MCL), hairy cell leukemia
(HCL), marginal zone lymphoma (MZL), Burkitt’s
lymphoma (BL), post-transplant lymphoproliferative dis-
order (PTLD), T-cell prolymphocytic leukemia (T-PLL),
B-cell prolymphocytic leukemia (B-PLL), Waldenström’s
macroglobulinemia, other NK- or T-cell lymphomas.
Multiple myeloma/plasma cell myeloma.
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Definition of inclusion criteria
Acute admission to the ICU: a non-planned admission.
It does not include planned recovery after surgery or
similar planned admissions. ICU admission does not in-
clude admissions to semi-intensive care, intermediate in-
tensive care or similar beds.
Age: the age of the patient in whole years at the time
of randomisation. The age will be calculated from date
of birth.
Shock: at least one of the following:
 Systolic pressure below 90 mmHg
 Mean arterial pressure below 70 mmHg
 Use of vasopressors or inotropes (norepinephrine,
epinephrine, phenylephrine, vasopressin or
dopamine, dobutamine, milirinone or
levosimendan)
 Lactate level 4 mmol/l or above
Renal replacement therapy: acute or chronic intermit-
tent or continuous renal replacement therapy.
Patients with expected duration of invasive mechanic-
ally ventilation longer than 24 hours: the treating clin-
ician estimates that the patient will be invasively
mechanically ventilated for more than 24 hours. When
there is doubt about this forecast the patient should be
enrolled.
Coagulopathy: platelets below 50 × 109/l or inter-
national normalised ratio (INR) above 1.5 or prothrom-
bin time (PT) above 20 s documented within the last
24 hours.
Treatment with anticoagulant drugs: ongoing treat-
ment with: dipyridamole, vitamin K antagonists, ADP-
receptor inhibitors, therapeutic doses of low-molecular-
weight heparin, new oral anticoagulant drugs, intraven-
ous direct thrombin (II) inhibitors and similar drugs.
Acetylsalicylic acid (all doses) and low-molecular-
weight heparin in prophylactic doses are not included.
History of coagulopathy: coagulopathy defined as
platelets below 50 × 109/l and/or INR above 1.5 and/or
PT above 20 s within the 6 months prior to hospital
admission.
History of chronic liver disease: portal hypertension,
cirrhosis proven by biopsy, CT scan or ultrasound, his-
tory of variceal bleeding or hepatic encephalopathy in
the past medical history.
Definition of exclusion criteria
Contraindications to proton pump inhibitors (PPIs): any
history of intolerance to PPIs or additives or treatment
with atazanavir (HIV medication).
Ongoing treatment with PPIs and/or histamine-2-
receptor antagonists (H2RAs): ongoing, documented
daily treatment with the drugs in the patient charts.
Gastrointestinal (GI) bleeding during current hospital
admission: GI bleeding of any origin (both upper and
lower) documented in the patient charts.
Peptic ulcer: peptic ulcer confirmed by endoscopy or
other method during current hospital admission.
Organ transplant: any kind of organ transplant during
current hospital admission.
Withdrawal from active therapy or brain death: pa-
tients where withdrawal or brain death is documented in
the patient charts.
Known pregnancy: fertile woman with a positive test
for urinary or plasma human chorionic gonadotropin
(hCG).
Consent not obtainable according to national regula-
tions: patients where the clinician or investigator is un-
able to obtain the necessary consent before inclusion of
the patient according to the national regulations.
Definition of baseline variables
Sex: the genotypic sex of the patient.
Age: defined in inclusion criteria.
Date of admission to hospital: the date of admission to
the first hospital the patient was admitted to during the
current hospital admission.
Elective surgery: surgery during the current hospital
admission scheduled 24 hours or more in advance.
Emergency surgery: surgery during current hospital
admission that was added to the operating room sched-
ule 24 hours or less prior to that surgery.
Medical admission: when no surgery has been per-
formed during the current hospital admission or surgery
has been performed more than 1 week prior to ICU
admission.
Treatment with anticoagulants at hospital admission
and at ICU admission: anticoagulants are defined in the
inclusion criteria.
Treatment with non-steroidal anti-inflammatory drugs
(NSAIDs) and acetylsalicylic acid at hospital admission:
treatment with all doses of these drugs at hospital
admission.
Treatment with intravenous thrombolysis: treatment
with all kinds of intravenous thrombolysis within 3 days
prior to randomisation.
Coagulopathy: defined in the inclusion criteria.
Treatment of suspected or confirmed Clostridium dif-
ficile infection (CDI) during current hospital admission.
Coexisting illnesses must have been present in the past
medical history prior to ICU admission and are defined
as follows:
 Chronic lung disease: chronic obstructive
pulmonary disease (COPD), asthma or other
chronic lung disease or treatment with any relevant
drug indicating this at admission to hospital
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 Previous myocardial infarction: history of
myocardial infarction
 Chronic heart failure: New York Heart Association
(NYHA) functional class III–IV. NYHA class III:
the patient has marked limitations in physical
activity due to symptoms (fatigue, palpitation or
dyspnoea) even during less than ordinary activity
(walking short distances 20–100 m or walking up
one flight of stairs). The patient is only comfortable
at rest. NYHA class IV: the patient is not able to
carry out any physical activity (without discomfort
(fatigue, palpitation or dyspnoea). Symptoms are
present even at rest and the patient is mostly
bedbound
 History of chronic renal failure: need of any form of
chronic renal replacement therapy within the last
year
 Liver disease: defined in baseline variables
 History of coagulopathy: defined in baseline
variables
 Immunosuppression: patients treated with at least
0.3 mg/kg/day of prednisolone equivalent for at
least 1 month in the 6 months prior to ICU
admission
 Metastatic cancer: proven metastasis by surgery,
CT scan or any other method
 Haematological malignancy: defined as stratification
variable
 AIDS: HIV-positive patients with one or more HIV-
defining diseases such as Pneumocystis jerovechii
pneumonia, Kaposi’s sarcoma, lymphoma, tubercu-
losis or toxoplasma infection
The Simplified Acute Physiology Score (SAPS II) is
based on the most extreme (highest or lowest) values
from 24 hours prior to randomisation. The score con-
sists of 17 variables: 12 physiological variables, age, type
of admission, and 3 variables related to underlying dis-
ease, to give a total score ranging from 0 to 163, with
higher scores indicating greater illness severity. The
score will be calculated from data from the 24 hours
prior to randomisation.
The Sequential Organ Failure Assessment (SOFA)
score will be calculated from raw physiology and treat-
ment data from the 24 hours prior to randomisation.
The SOFA score consists of weightings for six organ sys-
tems to give a total score ranging from 0 to 24, with
higher scores indicating a greater degree of organ
failure.
Definition of daily collected variables
Delivery of trial medication: confirmation of administra-
tion of the trial drug.
Treatment with a PPI or a H2RA: prescription of any
of these drugs in any dose (major protocol violation if
the treatment is initiated (e.g. as prophylaxis) without
clinical indication (e.g. GI bleeding).
Mechanical ventilation: invasive and non-invasive
mechanical ventilation including continuous mask con-
tinuous positive airway pressure (CPAP) or CPAP via a
tracheotomy. Intermittent CPAP is not mechanical
ventilation.
Circulatory support: continuous infusion of vasopres-
sor or inotrope (norepinephrine, epinephrine, phenyl-
ephrine, vasopressin or dopamine, dobutamine,
milirinone or levosimendan).
Renal replacement therapy: any form of renal replace-
ment therapy on this day. In patients receiving intermit-
tent renal replacement therapy days between treatments
are included.
Clinically important GI bleeding, onset of pneumonia,
CDI, and acute myocardial ischaemia in the ICU are de-
fined as outcomes.
Treatment with enteral feeding: any dose of enteral
feeding (including oral nutritional intake) during the
day.
Units of red blood cells: cumulated number of units of
red blood cells transfused during the day.
Serious adverse reactions (SARs) are defined below.
Definition of bleeding variables
Confirmed diagnosis: diagnosis/origin of bleeding con-
firmed by endoscopy or other method.
Verification of ulcer/gastritis/bleeding oesophageal
varices: confirmation of one of the three specific diagno-
ses by endoscopy or other method.
Haemostasis achieved or attempted: documentation in
patient charts of haemostasis achieved or attempted by
endoscopy, open surgery or coiling.
Definitions of outcome measures
Primary outcome:
90-day mortality: death from any cause within 90 days
following the day of randomisation.
Secondary outcomes:
proportion of patients with one or more of the follow-
ing adverse events: clinically important GI bleeding,
pneumonia, CDI, and acute myocardial ischaemia. The
events are defined as follows:
Clinically important GI bleeding: overt GI bleeding*
and at least one of the following four features within
24 hours of GI bleeding (in the absence of other causes)
in the ICU:
1. Spontaneous drop of systolic blood pressure, mean
arterial pressure or diastolic blood pressure of
20 mmHg or more
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2. Start of vasopressor or a 20 % increase in
vasopressor dose
3. Decrease in haemoglobin of at least 2 g/dl
(1.24 mmol/l)
4. Transfusion of two units of packed red blood cells
or more
*Overt GI bleeding: haematemesis, coffee ground em-
esis, melaena, haematochezia or bloody nasogastric
aspirate.
Pneumonia: episodes of newly confirmed pneumonia
according to the modified CDC criteria [47]:
 Two or more serial chest radiographs with at least
one of the following (one radiograph is sufficient
for patients with no underlying pulmonary or
cardiac disease):
1. New or progressive and persistent infiltrate
2. Consolidation
3. Cavitation
 and at least one of the following:
1. Fever (above 38 °C) with no other recognised
cause
2. Leucopoenia (white cell count below 4 × 109/l) or
leucocytosis (white cell count above 12 × 109/l)
 and at least two of the following:
1. New onset of purulent sputum or change in
character of sputum, or increased respiratory
secretions or increased suctioning requirements
2. New onset or worsening cough, or dyspnoea, or
tachypnoea
3. Rales or bronchial breath sounds
4. Worsening gas exchange (hypoxaemia, increased
oxygen requirement, increased ventilator
demand)
CDI: treatment with antibiotics (enteral vancomycin,
intravenous or enteral metronidazole, enteral fidaxomi-
cin) for suspected or proven CDI.
Acute myocardial ischemia: ST elevation myocardial
infarction, non-ST elevation myocardial infarction or un-
stable angina pectoris according to the criteria in the
clinical setting in question (e.g. elevated biomarkers, is-
chaemic signs on an electrocardiogram (ECG) and clin-
ical presentation) and receiving treatment as a
consequence of this (reperfusion strategies (percutan-
eous coronary intervention(PCI)/thrombolysis) or initi-
ation/increased antithrombotic treatment).
Proportions of patients with clinically important GI
bleeding: proportion of patients with one or more epi-
sodes of clinically important GI bleeding as defined above.
Proportion of patients with one or more infectious ad-
verse events: proportion of patients with one or more
episodes of pneumonia or CDI.
One-year mortality: landmark mortality 1 year post
randomisation.
Duration of life support in the ICU: the number of
days alive and free from respiratory or circulatory sup-
port and off renal replacement therapy as defined below.
The outcome will be days alive without the use of mech-
anical ventilation, circulatory support or renal replace-
ment therapy in the 90-day period, and will be defined
as the percentage of days without mechanical ventila-
tion, circulatory support, and renal replacement therapy
(as defined in daily collected variables) in the 90 days
after randomisation.
SARs: number of SARs as defined below.
The elements of all composite outcomes will be re-
ported in the supplementary material.
A health economic analysis will be performed. The
analytic details will be based on the result of the trial
and specified (cost-benefit versus cost-minimisation
analyses).
Definitions of serious adverse reactions (SARs)
A SAR is defined as any adverse reaction that results in
death, is life-threatening, requires hospitalisation or pro-
longation of existing hospitalisation, or results in persist-
ent or significant disability or incapacity.
Patients will be monitored for onset of SARs occurring
between the first dose of trial medication and until dis-
charge from the ICU. If the patient is readmitted to the
ICU and trial intervention is reintroduced, data collec-
tion for SARs will be resumed. If a patient experiences a
SAR the patient will be withdrawn from the trial inter-
vention but data collection and follow-up will be contin-
ued (see section 4.3.2).
SARs will be defined as follows:
Anaphylactic reactions defined as urticaria and at least
one of the following:
 Worsened circulation (more than 20 % decrease in
blood pressure or more than 20 % increase in
vasopressor dose)
 Increased airway resistance (more than 20 %
increase in the peak pressure on the ventilation)
 Clinical stridor or bronchospasm
 Subsequent treatment with bronchodilators
Agranulocytosis is defined as any new, acute and se-
vere drop in granulocytes to below 0.5 × 109/l requiring
active monitoring or treatment.
Pancytopenia is defined as any new, severe drop in red
blood cells, white blood cells and platelets requiring ac-
tive monitoring or treatment.
Acute hepatic failure is defined as severe and progres-
sing hepatic failure as judged by the treating physician
or the investigator.
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Stevens-Johnson syndrome and toxic epidermal necro-
lysis are defined as severe dermatological reactions with
a skin biopsy confirming the diagnosis.
Interstitial nephritis is defined as a nephritis affecting
the interstitium of the kidneys surrounding the tubules
with a kidney biopsy confirming the diagnosis.
Angioedema (Quincke’s oedema) is defined as a vascu-
lar reaction involving the deep dermis, subcutaneous or
submucosal tissues, resulting in a characteristic localised
oedema.
Appendix 2. Charter for the independent Data
Monitoring and Safety Committee (DMSC) of the
SUP-ICU trial
ClinicalTrials.gov Identifier: NCT02467621.
Research ethical committee number: H-15003141.
Introduction
The DMSC will constitute its own plan of monitoring
and meetings. However, this charter will define the mini-
mum of obligations and primary responsibilities of the
DMSC as perceived by the Steering Committee (SC), its
relationship with other trial components, its member-
ship, and the purpose and timing of its meetings. The
charter will also outline the procedures for ensuring
confidentiality and proper communication, the statistical
monitoring guidelines to be implemented by the DMSC,
and an outline of the content of the open and closed re-
ports which will be provided to the DMSC.
Primary responsibilities of the DMSC
The DMSC will be responsible for safeguarding the in-
terests of trial patients, assessing the safety and efficacy
of the interventions during the trial, and for monitoring
the overall conduct of the clinical trial. The DMSC will
provide recommendations about stopping or continuing
the trial to the SC of the SUP-ICU trial. To contribute
to enhancing the integrity of the trial, the DMSC may
also formulate recommendations relating to the selec-
tion/recruitment/retention of patients, their manage-
ment, improving adherence to protocol-specified
regimens and retention of patients, and the procedures
for data management and quality control.
The DMSC will be advisory to the SC. The SC will be
responsible for promptly reviewing the DMSC recom-
mendations, to decide whether to continue or terminate
the trial, and to determine whether amendments to the
protocol or changes in trial conduct are required.
The DMSC is planned by protocol to meet physically
in order to evaluate the planned interim analyses of the
SUP-ICU trial. The interim analyses will be performed
by an independent statistician selected by the members
of the DMSC (to be announced). The DMSC may add-
itionally meet whenever they decide or contact each
other by telephone or e-mail in order to discuss the
safety of trial participants. The sponsor has the responsi-
bility to report the overall number of serious adverse re-
actions (SARs) yearly to the DMSC. The DMSC can, at
any time during the trial, request the distribution of
events, including outcome measures and SARs accord-
ing to intervention groups. Further, the DMSC can re-
quest unblinding of the interventions if suggested by the
data; see section on ‘Closed sessions’. The recommenda-
tions of the DMSC regarding stopping, continuing or
changing the design of the trial should be communicated
without delay to the SC of the SUP-ICU trial. As soon
as possible, and no longer than 48 hours later, the SC
has the responsibility to inform all investigators of the
trial, and all the sites including patients in the trial,
about the recommendation of the DMSC and the SC de-
cision hereof.
Members of the DMSC
The DMSC is an independent multidisciplinary group
consisting of clinicians and a biostatistician that, collect-
ively, has experience in the management of ICU patients
and in the conduct, monitoring and analysis of rando-
mised clinical trials.
DMSC members
Anders Åneman, MD PhD.
Tim Walsh, professor, MD, PhD.
DMSC biostatistician
Aksel Karl Georg Jensen, Section of Biostatistics, Univer-
sity of Copenhagen.
Conflicts of interest
DMSC members will fill in and sign a declaration of
conflicts of interests. DMSC membership has been re-
stricted to individuals free of conflicts of interest. The
source of these conflicts may be financial, scientific, or
regulatory in nature. Thus, neither trial investigators nor
individuals employed by the sponsor, nor individuals
who might have regulatory responsibilities for the trial
products, are members of the DMSC. The DMSC mem-
bers do not own stock in the companies having products
being evaluated by the SUP-ICU trial.
The DMSC members will disclose to fellow members
any consulting agreements or financial interests they
have with the sponsor of the trial, with the Contract Re-
search Organisation (CRO) for the trial (if any), or with
other sponsors having products that are being evaluated
or having products that are competitive with those being
evaluated in the trial.
The DMSC will be responsible for deciding whether
these consulting agreements or financial interests ma-
terially impact their objectivity.
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The DMSC members will be responsible for advising
fellow members of any changes in these consulting
agreements and financial interests that occur during the
course of the trial. Any DMSC members who develop
significant conflicts of interest during the course of the
trial should resign from the DMSC.
DMSC membership is to be for the duration of the
clinical trial. If any members leave the DMSC during
the course of the trial, the SC will appoint their
replacement(s).
Formal interim analysis meetings
Two formal interim analysis meetings will be held to re-
view data relating to treatment efficacy, patient safety,
and quality of trial conduct. The three members of the
DMSC will meet when 90-day follow-up data of 1650
(approximately 50 % of sample size estimation) and 2500
(approximately 75 % of sample size estimation) patients
have been obtained.
Proper communication
To enhance the integrity and credibility of the trial, pro-
cedures will be implemented to ensure the DMSC has
sole access to evolving information from the clinical trial
regarding comparative results of efficacy and safety data,
aggregated by treatment group. An exception will be
made to permit access to an independent statistician
who will be responsible for serving as a liaison between
the database and the DMSC. At the same time, proce-
dures will be implemented to ensure that proper com-
munication is achieved between the DMSC and the trial
investigators. To provide a forum for exchange of infor-
mation among various parties who share responsibility
for the successful conduct of the trial, a format for open
sessions and closed sessions will be implemented. The
intent of this format is to enable the DMSC to preserve
confidentiality of the comparative efficacy results while
at the same time providing opportunities for interaction
between the DMSC and others who have valuable in-
sights into trial-related issues.
Closed sessions
Sessions involving only DMSC members who generate
the closed reports (called closed sessions) will be held to
allow discussion of confidential data from the clinical
trial, including information about the relative efficacy
and safety of interventions. In order to ensure that the
DMSC will be fully informed in its primary mission of
safeguarding the interest of participating patients, the
DMSC will be blinded in its assessment of safety and ef-
ficacy data. However, the DMSC can request unblinding
from the SC.
Closed reports will include analysis of the primary out-
come measure. In addition, analyses of the secondary
outcome measures and SARs will also be reported.
These closed reports will be prepared by an independent
biostatistician being a member of the DMSC, with assist-
ance from the trial data manager, in a manner that al-
lows them to remain blinded. The closed reports should
provide information that is accurate, with follow-up on
mortality that is complete to within 2 months of the date
of the DMSC meeting.
Open reports
For each DMSC meeting, open reports will be made
available to all who attend the DMSC meeting. The re-
ports will include data on recruitment and baseline char-
acteristics, pooled data on eligibility violations,
completeness of follow-up, and compliance. The inde-
pendent statistician, being a member of the DMSC, will
prepare these open reports in cooperation with the trial
data manager.
The reports should be provided to DMSC members
approximately 3 days prior to the date of the meeting.
Minutes of the DMSC meetings
The DMSC will prepare minutes of their meetings. The
closed minutes will describe the proceedings from all
sessions of the DMSC meeting, including the listing of
recommendations by the committee. Because it is pos-
sible that these minutes may contain unblinded informa-
tion, it is important that they are not made available to
anyone outside the DMSC.
Recommendations to the Steering Committee
After the interim analysis meetings, the DMSC will
make a recommendation to the SC to continue, hold or
terminate the trial.
Interim analyses will be conducted after patient num-
ber 1650 and patient number 2500 have been followed-
up for 90 days.
The DMSC will recommend pausing or stopping the
trial if group difference in the primary outcome measure,
SARs or SUSARs are found at the interim analyses with
statistical significance levels adjusted according to the
LanDeMets group sequential monitoring boundaries
based on the O’Brien-Fleming alpha-spending function
[48]. If an analysis of the interim data from 1650/2500
patients fulfils the LanDeMets stopping criterion the in-
clusion of further patients will be paused and an analysis
including patients randomised during the analysis period
will be performed. If this second analysis also fulfils the
LanDeMets stopping criterion according to the group
sequential monitoring boundaries the DMSC will rec-
ommend stopping the trial [49]. Furthermore, the
DMSC can recommend pausing or stopping the trial if
continued conduct of the trial clearly compromises pa-
tient safety. However, stopping for futility to show an
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intervention effect of 15 % RRR will not be an option as
intervention effects less than 15 % RRR of all-cause mor-
tality may also be clinically relevant.
This recommendation will be based primarily on safety
and efficacy considerations and will be guided by statis-
tical monitoring guidelines defined in this charter and
the trial protocol.
The SC is jointly responsible with the DMSC for safe-
guarding the interests of participating patients and for the
conduct of the trial. Recommendations to amend the
protocol or conduct of the trial made by the DMSC will
be considered and accepted or rejected by the SC. The SC
will be responsible for deciding whether to continue, hold
or stop the trial based on the DMSC’s recommendations.
The DMSC will be notified of all changes to the
trial protocol or conduct. The DMSC concurrence
will be sought on all substantive recommendations or
changes to the protocol or trial conduct prior to their
implementation.
Statistical monitoring guidelines
The outcome parameters are defined in the statistical
analyses plan in the protocol. For the two intervention
groups, the DMSC will evaluate data on:
The primary outcome measure
Mortality 90 days after randomisation of each patient
(‘landmark mortality’).
The secondary outcome measures
 Proportion of patients with one or more of the
following adverse events: clinically important
gastrointestinal (GI) bleeding, pneumonia,
Clostridium difficile infection (CDI), and acute
myocardial ischaemia
 Proportion of patients with clinically important GI
bleeding
 One-year mortality post randomisation
 The occurrence of SARs in the ICU
The DMSC will be provided with these data from the
coordinating centre as:
Number of patients randomised.
Number of patients randomised per intervention group.
Number of patients stratified pr. stratification variable
per intervention group.
Number of events, according to the outcomes, in the
two groups.
Based on evaluations of these outcomes, the DMSC will
decide if they want further data from the coordinating
centre and when to perform the next analysis of the data.
For analyses, the data will be provided in one file as
described below.
The DMSC should be informed yearly about SARs oc-
curring in the two groups of the trial.
The DMSC may also be asked to ensure that proce-
dures are properly implemented to adjust trial sample
size or duration of follow-up to restore power if
protocol-specified event rates are inaccurate. If so, the
algorithm for doing this should be clearly specified.
Conditions for transfer of data from the coordinating
centre to the DMSC
The DMSC will be provided with a file containing the
data defined as follows:
Row 1 contains the names of the variables (defined
below).
Row 2 to N (where N − 1 is the number of patients
having entered the trial) each contains the data of one
patient.
Column 1 to p (where p is the number of variables to be
defined below) each contains in row 1 the name of a vari-
able and in the next N rows the values of this variable.
The values of the following variables should be in-
cluded in the database:
1. screening_id: a number that uniquely identifies the
patient
2. rand_code: the randomisation code (group 0 or 1).
The DMSC is not to be informed on what
intervention the groups received
3. clin_imp_bleed: clinically important GI bleeding (1
= the patient had one or more episodes, 0 = the
patient did not)
4. pneumonia: onset of pneumonia in the ICU after
randomisation (1 = one or more episodes, 0 = no
episodes)
5. clostridium: Clostridium difficile infection (1 = one
or more episodes, 0 = no episodes)
6. ami: acute myocardial ischemia in the ICU (1 = one
or more episodes, 0 = no episodes)
7. SAR: SAR indicator (1 = one or more SARs, 0 = no
SARs).
Appendix 3. Power estimations
All power estimations have been calculated on data from
the international 7-day inception cohort study [9].
Since we do not know whether treatment with acid sup-
pressants reduce or increase mortality, a number of scenar-
ios have been considered (±20 relative risk reduction):
1. 25.0 % mortality 90 days after inclusion among pa-
tients with:
At least one risk factor*.
No acid suppressants at ICU admission.
Treatment with acid suppressants during ICU admission.
No clinically important bleeding** during ICU admission.
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Power estimation
ARR absolute risk reduction
We do not know whether a PPI benefits or harms the
patients, and need to include both scenarios. With 1671
patients in each group we will be able to show an abso-
lute increase in risk of 5 % with 90 % power at the pri-
mary outcome, but also an absolute risk reduction of
5 % with 90 % power.
The sample size has been calculated on patients fulfill-
ing inclusion and exclusion criteria in the SUP-ICU trial
and because few patients were not treated with acid sup-
pressants during ICU admission, the estimation is based
on the group receiving acid suppressants (intervention
group).
2. 25.9 % mortality 90 days after inclusion among pa-
tients with:
At least one risk factor*.
No acid suppressants at ICU admission.
Treatment with acid suppressants during ICU
admission.
Bleeding (overt or clinically important**) or no
bleeding during ICU admission.
Power estimation
ARR absolute risk reduction
3. 29.2 % mortality 90 days after inclusion among pa-
tients with:
At least one risk factor*.
Acid suppressants and no acid suppressants at ICU
admission.
Treatment with acid suppressants during ICU
admission.
No bleeding (overt or clinically important**) during
ICU admission.
Power estimation
ARR absolute risk reduction
4. 30.5 % mortality 90 days after inclusion among pa-
tients with:
At least one risk factor*.
Acid suppressants or no acid suppressants at ICU
admission.
Treatment with acid suppressants during ICU admission.
Bleeding (overt or clinically important**) or no
bleeding during ICU admission.
Power estimation
ARR absolute risk reduction
*Risk factors are: shock, renal replacement therapy, co-
agulopathy, and coagulopathy and liver disease as
comorbidities.
**Overt bleeding is defined as any episode of haema-
temesis, coffee ground emesis, melaena, haematochezia
or bloody nasogastric aspirate.
Clinically important bleeding is defined as overt bleed-
ing and at least one of the following four features within
24 hours of GI bleeding (in the absence of other causes)
[1, 5] in the ICU:
a) Spontaneous drop of systolic blood pressure, mean
arterial pressure or diastolic blood pressure of
20 mmHg or more
b) Start of vasopressor or a 20 % increase in
vasopressor dose
c) Decrease in haemoglobin of at least 2 g/dl
(1.24 mmol/l)
d) Transfusion of two units of packed red blood cells
or more.
ARR Power Patients per group
−5 % 80 % 1091
90 % 1461
+5 % 80 % 1248
90 % 1671
ARR Power Patients per group
−5.2 % 80 % 1034
90 % 1384
+5.2 % 80 % 1180
90 % 1579
ARR Power Patients per group
−5.8 % 80 % 901
90 % 1206
+5.8 % 80 % 1014
90 % 1357
ARR Power Patients per group
−6.1 % 80 % 837
90 % 1120
+6.1 % 80 % 937
90 % 1254
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Appendix 4
Fig. 1
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Appendix 5. Trial sequential analysis of all-cause
mortality (16 trials)
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